The United States Food and Drug Administration has approved SimpleScreen CRC, a blood-based test developed by Freenome for colorectal cancer screening in adults aged 45 and older who are considered at average risk.
The test analyzes DNA fragments circulating in a person’s blood for molecular signals associated with colorectal cancer. Unlike a colonoscopy, it does not directly examine the colon or permit a physician to remove a suspicious growth. Unlike stool-based screening, it requires a standard blood draw rather than a sample collected at home.
Freenome and Abbott announced the approval on Monday, July 27. Abbott holds exclusive rights to commercialize the test in the United States and says it intends to introduce it during the autumn of 2026. The companies have not announced a precise nationwide launch date or a standard retail price.
The approval applies to adults who do not have symptoms and who are not already considered at elevated risk because of factors such as a personal history of colorectal cancer, certain inherited conditions or other significant medical history. People with symptoms or elevated risk may require a different diagnostic or screening process.
The authorization gives patients and clinicians another non-invasive screening option. It does not make the blood test a replacement for colonoscopy, and a positive result must be investigated through a follow-up colonoscopy.
What Is Confirmed
The FDA approval itself is supported by the joint company announcement and independently reported by Reuters.
SimpleScreen CRC was evaluated through a clinical programme that enrolled more than 48,000 adults at over 200 sites. Reuters reported that the prespecified analysis found the test detected 81.1 per cent of colorectal cancers present among the evaluated participants.
That figure is the test’s reported sensitivity for cancer. It means the test identified approximately 81 of every 100 cancers represented in that analysis. It does not mean that every positive result indicates cancer, nor does it mean the test is 81.1 per cent accurate in every population or clinical setting.
The reported sensitivity for advanced precancerous growths was substantially lower: 13.7 per cent overall and 30.7 per cent for growths categorized as high risk. This difference is important because screening can reduce cancer deaths both by finding established cancers earlier and by identifying precancerous growths before they become malignant.
The American Cancer Society updated its colorectal cancer screening guidance in May 2026 to include blood-based screening as an option. It continues to prefer colonoscopy and stool-based tests because those methods are generally more effective at finding precancerous growths and early-stage disease. The society recommends blood-based testing primarily for people who are unwilling or unable to complete a preferred screening method.
The society continues to recommend that average-risk adults begin screening at age 45. A positive result from any non-colonoscopy screening test should be followed by a timely colonoscopy.
What Remains Unclear
The approval does not establish how widely the test will be used.
Abbott has said it plans a U.S. launch this fall, but the companies have not provided a precise release date, expected patient price or detailed information about which private insurance plans will initially cover it.
The companies say the test meets existing Medicare coverage criteria. Actual payment, coding and patient-access arrangements may still depend on the test’s implementation within federal and private insurance systems. Medicare policy covers qualifying blood-based colorectal screening tests, but coverage rules include eligibility, testing-frequency and follow-up requirements.
The approval also does not demonstrate how many additional people will undergo screening because a blood option is available. A test that is easier to complete may increase participation, but the scale of that increase will require real-world evidence.
The long-term effect on colorectal cancer mortality is similarly unknown. Regulatory approval is based on evidence that the test can detect defined biological signals with specified performance. Demonstrating fewer late-stage diagnoses or deaths requires longer observation and comparison with existing screening strategies.
This U.S. authorization does not establish whether the test has been submitted to, reviewed by or authorized by Canadian or Mexican regulators. No conclusion about availability elsewhere in North America was drawn from the sources examined.
The Wider Context
Colorectal cancer screening presents an unusual public-health problem: several effective testing methods already exist, but many eligible adults do not complete them on schedule.
Colonoscopy allows clinicians to examine the colon and remove suspicious polyps during the same procedure. It is nevertheless more invasive than other screening methods and normally requires bowel preparation, time away from work, transportation and, in many cases, sedation.
Stool-based tests can be completed at home and are generally better than current blood tests at identifying precancerous growths. Some patients nevertheless delay or avoid them because of discomfort with sample collection, uncertainty about instructions or failure to return the kit.
A blood test can be incorporated into a routine medical visit. Its principal potential advantage is therefore not that it outperforms all existing methods, but that it may reach people who otherwise would not be screened.
That distinction is visible in the American Cancer Society’s guidance. Blood-based testing is included as an option, but it is not treated as clinically interchangeable with colonoscopy or the preferred stool-based methods.
The practical public-health question is consequently not limited to whether SimpleScreen detects cancer. It is whether the combination of its performance, accessibility, cost, follow-up rates and patient acceptance produces better outcomes than the screening that people would otherwise receive—or fail to receive.
What Happens Next
Abbott is expected to prepare the test for commercial introduction in the United States during the autumn.
Health systems, laboratories, insurers and clinicians will need operational information concerning ordering, sample handling, result interpretation, reimbursement and referral for follow-up colonoscopy.
Patients receiving a positive result will still require colonoscopy to determine whether cancer or a precancerous growth is present. A negative result will not eliminate the possibility of disease, particularly because the test did not detect every cancer or most advanced precancerous lesions in the reported study.
Researchers and regulators will be able to evaluate real-world screening participation, false-positive and false-negative results, follow-up completion and diagnosis rates after the test enters broader use.
Future studies may also examine whether improved blood-test technology can increase detection of precancerous growths without producing an unacceptable number of false-positive results.